Capmatinib for metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer granted priority regulatory review in the US
The FDA have granted priority review for this selective MET inhibitor on the basis of the GEOMETRY mono-1 Phase II study, which demonstrated an overall response rate of 67.9% and 40.6% among treatment-naïve and previously treated patients, respectively.
Source:
PharmaTimes